Abvc biopharma adhd phase ii part 2 clinical study first subject enrolled at ucsf

Fremont, c, june 12, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc) (“company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neuropsychiatric conditions, and ophthalmology, today announced that the first subject was enrolled at university of california san francisco (ucsf) medical center on june 9, 2023. the ucsf site, led by professor keith mcburnett, phd, psychiatry ucsf weill institute for neurosciences, joins the five (5) taiwan sites that have begun patient enrollment for the company's adhd phase ii part 2 clinical study.
ABVC Ratings Summary
ABVC Quant Ranking